271980 — Jeil Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩219bn
- KR₩295bn
- KR₩705bn
- 51
- 83
- 50
- 71
Annual income statement for Jeil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 691,325 | 700,693 | 722,230 | 726,394 | 704,542 |
| Cost of Revenue | |||||
| Gross Profit | 156,691 | 155,976 | 156,798 | 184,256 | 177,495 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 677,789 | 709,070 | 735,734 | 717,662 | 723,811 |
| Operating Profit | 13,536 | -8,377 | -13,504 | 8,731 | -19,269 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 12,552 | -13,834 | -13,247 | 1,916 | -26,959 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 6,965 | -14,986 | -15,009 | 5,201 | -30,143 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 6,916 | -12,473 | -13,091 | 5,005 | -29,968 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 6,916 | -12,473 | -13,091 | 5,005 | -29,968 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 449 | -951 | -899 | 343 | -2,042 |
| Dividends per Share |